Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us […]
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO — Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative breast cancer led to similar cumulative progression-free survival (PFS) in a large randomized trial. Patients who received a CDK4/6 inhibitor plus an aromatase inhibitor (AI) as initial therapy and fulvestrant in the second line had a median PFS of 31.0 months at […]
Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer
MIAMI BEACH — After a bumpy start, CDK4/6 inhibitors have started to gain traction in early hormone receptor (HR)-positive/HER2-negative breast cancer, according to recent data. Two negative phase III trials of palbociclib (Ibrance) questioned whether the transformative impact of CDK4/6 inhibition in advanced HR+/HER2- breast cancer would carry over into early disease. More recently, the […]